Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.94 USD
-0.08 (-1.99%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AQST 3.94 -0.08(-1.99%)
Will AQST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AQST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AQST
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
AQST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Other News for AQST
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business ...
Commit To Buy Aquestive Therapeutics At $2.50, Earn 32.4% Annualized Using Options
Aquestive Therapeutics (AQST) Appoints New Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer | AQST Stock News
Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer